Sirnaomics Says siRNA Effective in Phase II Basal Cell Carcinoma Trial
publication date: Feb 23, 2022
Sirnaomics (HK: 2257) reported positive interim data from a US Phase II trial of STP705, a siRNA (small interfering RNA) drug, for patients with cutaneous basal cell carcinoma. A total of 15 patients were enrolled, five in each of three cohorts of a dose escalation trial. In the two largest dose cohorts, three of the five patients experienced a complete response, while one in the lowest dose group also had a complete response. In general, patients showed an improved or stable cosmetic result with no significant cutaneous skin reactions. Sirnaomics is a Maryland-Suzhou siRNA company. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.